Treatment protocols for non-small cell lung cancer

INTRODUCTION — The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with non-small cell lung cancer. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with non-small cell lung cancer. Additional regimens may be added over time, particularly as treatment for non-small cell lung cancer evolves.

This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with non-small cell lung cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:

●(See "Initial management of advanced non-small cell lung cancer lacking a driver mutation".)

●(See "Subsequent line therapy in non-small cell lung cancer lacking a driver mutation".)

●(See "Systemic therapy in resectable non-small cell lung cancer".)

These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.

REGIMENS

Carboplatin plus docetaxel —  (table 1)

Carboplatin plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel) —  (table 2)

Carboplatin, paclitaxel, atezolizumab, and bevacizumab —  (table 3)

Carboplatin plus pemetrexed —  (table 4)

Cisplatin plus pemetrexed —  (table 5)

Gemcitabine plus carboplatin —  (table 6)

Gemcitabine plus cisplatin (GC) —  (table 7)

Paclitaxel carboplatin —  (table 8)

Paclitaxel, carboplatin, and bevacizumab —  (table 9)

Pembrolizumab monotherapy —  (table 10)

Pembrolizumab, nabpaclitaxel, and carboplatin —  (table 11)

Pembrolizumab, paclitaxel, and carboplatin —  (table 12)

Pembrolizumab, pemetrexed, and carboplatin —  (table 13)

Nivolumab monotherapy —  (table 14)

Vinorelbine plus cisplatin —  (table 15)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Diagnosis and management of lung cancer".)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.